Form 4: Castle Biosciences CEO Derek Maetzold Sells Shares Under 10b5-1 Plan

Castle Biosciences' CEO, Derek Maetzold, executed multiple sales of common stock on October 8, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On October 8, 2024, Derek J Maetzold, the President and CEO of Castle Biosciences, sold shares of the company's common stock.
• The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on May 24, 2024.
• Maetzold sold a total of 986 shares directly at a price of $30.269 per share.
• Additional shares were sold indirectly through various trusts for which Maetzold serves as trustee or has beneficiary relationships.
• These trusts include The Maetzold Descendants 2020 Trust, Derek Maetzold 2020 Irrevocable Trust, and several Maetzold 2018 Remainder Trusts.
• The weighted-average sale price for the transactions was $30.269, with individual trades ranging from $30.00 to $30.41.
• Following the reported transactions, Maetzold directly owns 93,636 shares of Castle Biosciences common stock.
• Maetzold also indirectly owns shares through various trusts, including 122,866 shares through DJM Grantor Retained Annuity Trust No. 5 and 26,134 shares through DJM Grantor Retained Annuity Trust No. 6.

Sentiment

Score: 5

Explanation: Neutral sentiment as the stock sales were conducted under a pre-arranged 10b5-1 plan, suggesting routine portfolio management rather than a negative outlook on the company.

Positives

• The sales were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Negatives

• The CEO selling shares, even under a pre-arranged plan, could be perceived negatively by some investors.

Risks

• Continued sales by insiders could put downward pressure on the stock price.
• Investor sentiment could be negatively affected if sales are perceived as a lack of confidence in the company's future prospects.

Industry Context

Insider sales are a common occurrence in publicly traded companies. The use of 10b5-1 plans allows insiders to sell shares without being accused of trading on material non-public information. Investors often monitor insider transactions as an indicator of management's confidence in the company's prospects.

Comparison to Industry Standards

• Comparing insider trading activity to similar companies in the biotechnology sector can provide context.
• Companies like Exact Sciences (EXAS) and Myriad Genetics (MYGN) also have executives who periodically execute stock sales.
• The size and frequency of these sales, as well as the use of 10b5-1 plans, are typical benchmarks for comparison.

Stakeholder Impact

• Shareholders may react to the news of insider selling, potentially impacting the stock price.
• Employees may be concerned about the implications of insider selling, although the use of a 10b5-1 plan mitigates some concerns.

Key Dates